GSK, Human Genome Sciences To Co-Develop Antibody For Cancer Treatment
This article was originally published in The Pink Sheet Daily
Human Genome Sciences has completed a Phase II trial of HGS-ETR1 for non-small cell lung cancer, with trials ongoing for non-Hodgkin's lymphoma and colorectal cancer.
You may also be interested in...
Human monoclonal antibody is in clinical development for the treatment of rheumatoid arthritis and systematic lupus erythematosus. The two firms will share jointly in Phase III and IV development costs, as well as in sales and profits.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.